市場調査レポート

体外診断 (IVD) の中国市場

IVD in China

発行 Kalorama Information 商品コード 333253
出版日 ページ情報 英文 264 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
体外診断 (IVD) の中国市場 IVD in China
出版日: 2015年06月11日 ページ情報: 英文 264 Pages
概要

人口10億人以上を抱える中国は、過去10年、実質GDPの平均成長率において世界経済を牽引しており、体外診断薬 (IVD) 市場においても、米国、西欧諸国、日本といった先進国に次ぐ規模となっています。中国はアジア太平洋地域最大の臨床試験所市場のひとつであり、IVD市場主要10か国の中で最速で成長しています。

当レポートでは、中国におけるIVD市場の現状と2024年までの予測、セグメント別の市場規模と成長予測、SWOT分析、および参入企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 途上国における医療および診断薬のイントロダクション:中国の状況

  • 背景
  • 人口動向と疾患人口統計
  • 肥満
  • 糖尿病
  • アレルギーおよび喘息
  • 心血管疾患
  • 新興ウイルスおよび疾患
  • 抗菌剤耐性
  • 臨床試験所検査
  • 市場セグメント別機会
  • 中国の将来的経済成長
  • BRIC指標:中国のIVD市場
  • IVD投資

第3章 中国のIVD市場に関するSWOT分析

  • イントロダクション
  • 強み:市場の成長を促す状況
    • 新興の中国医療市場に対する政府の支援
    • 欧米スタイルの医薬品
    • 勢いのあるバイオテクノロジー業界
    • 研究受託と高度技術
    • 科学者の帰還
    • 病院部門の拡大
    • 臨床試験所の拡大
  • 弱み:市場の成功および参入の障壁となる因子
    • 東洋医学
    • 病院の資源の制約
    • 文化とビジネス環境
    • 知的財産問題
    • 品質および安全性問題
    • 医療保険
    • 法規制:製品認可と治験
    • 法規制:医療サービスコスト管理
    • 流通問題
  • 機会:地方の医療と技術パートナーシップ
  • 脅威:国内における競争と政府の政策

第4章 中国IVD市場規模

  • イントロダクション
  • 市場
  • 市場全体
    • 免疫測定
    • 臨床化学
    • 血液学
    • ポイントオブケア
    • 分子
    • 尿検査
    • その他のIVD検査

第5章 中国における業界および企業活動

  • イントロダクション
  • 中国市場のリーダー
  • 国際的IVD企業
  • 中国国内のIVD企業

図表

目次
Product Code: KLI5586455

With a population of more than 1 billion, China is the world's largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro diagnostics (IVD) market, China trails only the populous, developed markets of the United States, western European countries, and Japan. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets.

This report places China and its IVD market in context with the developing world in terms of diseases, economic and healthcare system development, and other key metrics related to health expenditures and diagnostics. China as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and India; collectively with China referred to as “BRIC” nations. China and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, obesity and diseases of aging.

IVD in China presents current analysis of the Chinese IVD industry and provides forecasts to 2024. The report takes an in-depth look at the market, providing data on the size and growth of the total Chinese market as well as on the following IVD in China market segments:

  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Point of Care/OTC
  • Molecular
  • Urinalysis
  • Other IVD Tests

IVD in China presents the main issues and trends affecting this market, influencing its move into the future. Some of these include:

  • The Future of Chinese Economic Growth
  • Chinese Healthcare Reform and Hospital Infrastructure
  • Market Barriers - Regulation, Policy and Distribution
  • Market Segment Opportunities
  • BRIC Metrics - Chinese IVD Market in Context
  • IVD Spending
  • Strengths - Conditions That Support Market Growth
  • Weaknesses - Factors That Pose Barriers to Market Success and Entry
  • Opportunities - Rural Healthcare and Technology Partnerships
  • Threats - Domestic Competition and Government Policy

The report provides detailed information regarding the IVD industry and company activity in China. Recent activity of international IVD Companies in China is presented. Companies discussed include:

  • Abbott Laboratories
  • Affymetrix, Inc.
  • ALERE
  • Arkray
  • Axis-Shield, plc
  • Beckman Coulter, Inc./Danaher
  • Becton, Dickinson & Co.
  • Biohit Oy
  • bioMérieux, Inc.
  • Bio-RAD Laboratories, Inc.
  • Danaher Corp.
  • Gen-Probe, Inc.
  • Hologic, Inc.
  • Horiba Medical
  • Instrumentation Laboratory
  • IRIS International, Inc.
  • Laboratory Corporation of America
  • Life Technologies Corporation
  • Luminex Corporation
  • MedMira
  • Myriad Genetics
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Phadia AB
  • Promega Corporation
  • QIAGEN N.V.
  • Radiometer A/S
  • Roche
  • Siemens
  • SuperNova Diagnostics, Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific

Recent activity of Chinese IVD companies is discussed as well. Companies examined include:

  • Autobio Group
  • BioSino Bio-Technology and Science, Inc.
  • CapitalBio Corporation
  • Caretium Medical Instruments
  • Chemtron Biotech Co., Ltd.
  • China Health Labs & Diagnostics, Ltd.
  • Daan Gene Co., Ltd.
  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Hai Kang Life Corporation
  • Shanghai Kehua Bio-engineering
  • Beijing Leadman Biochemistry Co., Ltd.
  • Mindray Medical International, Ltd.

Information for this report was gathered from a wide variety of published sources including company reports, catalogs, materials and public filings; government documents; trade journals; newspapers and business press; analysts' reports and other sources. Interviews with industry experts were conducted to capture the perspectives from market participants' point of view and assess trends, and form the basis of the forecasting and competitive analysis. Sales estimates are provided for the historic 2009 to 2014 period and forecasts are provided through 2024. The size of each market segment refers to manufacturers' revenues in U.S. dollars.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Major Findings of the Report
  • China in Context - A Developing Economy with Developed World Problems
  • Demographic Aging
  • Disease Drivers
  • Infectious Disease Threats
  • Chinese Economy
  • IVD Market in the BRIC Countries
  • IVD Market in China
  • Chinese Healthcare Reform and Hospital Infrastructure
  • Market Barriers - Regulation, Policy and Distribution
  • Regulation and Policy Challenges for International Companies
  • Distribution in China

TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT

  • Background
  • Population Trends and Disease Demographics
  • Obesity
  • Disease Trends
  • Diabetes
  • Cancer
  • Allergy and Asthma
  • Cardiovascular Disease
  • Emerging Viruses and Diseases
  • Antimicrobial Drug Resistance
  • Clinical Lab Tests
  • Types of Tests
  • Venues for Test Usage
  • Market Segment Opportunities
  • Point-of-Care (POC) Testing
  • Core Lab Tests
  • Molecular Assays
  • Hematology
  • Coagulation
  • Microbiology
  • Tests Used in Blood Banking
  • Histology and Cytology
  • The Future of Chinese Economic Growth
  • Strong Capital Markets and M&A Activity
  • Rising Standards of Living
  • Corruption and Bribery
  • BRIC Metrics - Chinese IVD Market in Context
  • Available Markets - Urban Populations in BRIC Countries
  • Paying for Healthcare - Government Expenditures and the Culture of Spending
  • Healthcare Capacities in BRIC Nations - A Work in Progress
  • IVD Spending
  • Will China Capture the IVD Industry?

THREE: CHINA IVD SWOT ANALYSIS

  • Introduction
  • Strengths - Conditions That Support Market Growth
  • Government Support of the Emerging Chinese Healthcare Market
  • Western-Style Pharmaceuticals
  • Thriving Biotech Industry
  • Contract Research and High Technology
  • Returning Scientists
  • Growing Hospital Sector
  • Expanding Clinical Labs
  • Weaknesses - Factors That Pose Barriers to Market Success and Entry
  • Traditional Chinese Medicine
  • Resource Constraints in Hospitals
  • Culture and Business Environment
  • Intellectual Property Issues
  • Quality and Safety Concerns
  • Healthcare Insurance
  • Regulation - Product Approval and Clinical Trials
  • Regulation - Healthcare Service Cost Controls
  • Distribution Challenges
  • Opportunities - Rural Healthcare and Technology Partnerships
  • Threats - Domestic Competition and Government Policy
  • Domestic Competition
  • Government Policy and Price Setting

FOUR: CHINA IVD MARKET SIZE

  • Introduction
  • The Market
  • Total Chinese IVD Market
  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Point of Care/OTC
  • Molecular
  • Urinalysis
  • Other IVD Tests

FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA

  • Introduction
  • Market Leaders in China
  • International IVD Companies - Recent Activity
  • Abbott Laboratories
  • Affymetrix, Inc.
  • ALERE
  • Arkray
  • Axis-Shield, plc
  • Beckman Coulter, Inc./Danaher
  • Becton, Dickinson & Co.
  • Biohit Oy
  • bioMérieux, Inc.
  • Bio-RAD Laboratories, Inc
  • Danaher Corp.
  • Gen-Probe, Inc.
  • Hologic, Inc.
  • Horiba Medical
  • Instrumentation Laboratory
  • IRIS International, Inc.
  • Laboratory Corporation of America
  • Life Technologies Corporation
  • Luminex Corporation
  • MedMira
  • Myriad Genetics
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Phadia AB
  • Promega Corporation
  • QIAGEN N.V.
  • Radiometer A/S
  • Roche
  • Siemens
  • SuperNova Diagnostics, Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific
  • Chinese IVD Companies - Recent Activity
  • Autobio Group
  • BioSino Bio-Technology and Science, Inc.
  • CapitalBio Corporation
  • Caretium Medical Instruments
  • Chemtron Biotech Co., Ltd.
  • China Health Labs & Diagnostics, Ltd.
  • Daan Gene Co., Ltd.
  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Hai Kang Life Corporation
  • Shanghai Kehua Bio-engineering
  • Beijing Leadman Biochemistry Co., Ltd.
  • Mindray Medical International, Ltd.

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Exhibit 1-1: Global Map of China
  • Exhibit 1-2: Industrial Map of China
  • Table 1-1: BRIC IVD Markets by Country, 2014-2019
  • Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014

TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT

  • Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries(2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World)
  • Table 2-2: Selected Worldwide Disease Statistics, 2014
  • Exhibit 2-1: Diabetes Population by Country, 2015
  • Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China)
  • Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015
  • Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
  • Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
  • Exhibit 2-4: Chinese GDP per Capita by Province, 2012
  • Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
  • Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
  • Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, SouthKorea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy)
  • Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries(Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy,Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand,
  • Turkey, United Kingdom, United States, Vietnam)
  • Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014(United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India)
  • Table 2-10: BRIC IVD Markets by Country, 2014-2019
  • Table 2-11: Selected Made-in-China Lab Supplies

THREE: CHINA IVD SWOT ANALYSIS

  • Exhibit 3-1: Chinese Hospitals by Tier
  • Exhibit 3-2: Hospital Count by Certification Status, 2014
  • Exhibit 3-3: Ethnolinguistic Map of China
  • Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
  • Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
  • Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality

FOUR: CHINA IVD MARKET SIZE

  • Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other)
  • Table 4-1: Total IVD Sales in China, 2014-2024
  • Exhibit 4-2: Total IVD Sales in China, 2014-2024
  • Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
  • Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
  • Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
  • Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
  • Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
  • Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
  • Table 4-5: Immunoassay Sales in China, 2014-2024
  • Exhibit 4-6: Immunoassay Sales in China, 2014-2024
  • Table 4-6: Clinical Chemistry Sales in China, 2014-2024
  • Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
  • Table 4-7: Hematology Sales in China, 2014-2024
  • Exhibit 4-8: Hematology Sales in China, 2014-2024
  • Table 4-8: Point of Care/OTC Sales in China, 2014-2024
  • Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
  • Exhibit 4-10: Selected Point of Care/OTC Products Sold in China
  • Table 4-9: Molecular Test Sales in China, 2014-2024
  • Exhibit 4-11: Molecular Test Sales in China, 2014-2024
  • Table 4-10: Urinalysis Test Sales in China, 2014-2024
  • Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
  • Table 4-11: Other IVD Test Sales in China, 2014-2024
  • Exhibit 4-13: Other IVD Test Sales in China, 2014-2024

FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA

  • Table 5-1: Leading Global IVD Companies in China
  • Table 5-2: Leading Domestic IVD Companies in China
  • Table 5-3: Leading Chinese IVD Companies
Back to Top